Skip to main content
Equibles
EYPT logo

EYPT · EyePoint, Inc. · Webcasts, Transcripts & Audio

Track EYPT — free

Use EYPT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EYPT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.15 -0.10 (-3.08%) At close · Oct 5
Russell 2000 member Rebalance outlook locked
Market Cap
$312.09M
Shares
86.21M
Volume · Oct 5 2.76M Avg daily vol (3M) 3.88M

EyePoint, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for EyePoint, Inc. (EYPT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲26.9% $9.29M −$20.98M '22 Q1 22-05-04 ▲28.3% $11.56M −$19.41M '22 Q2 22-07-18 ▲10.5% $10.01M −$18.42M '22 Q3 22-11-02 ▼8.8% $10.53M −$43.45M '22 Q4 23-01-06 ▼17.3% $7.68M −$21.16M '23 Q1 23-05-03 ▼21.3% $9.11M −$22.92M '23 Q2 23-08-02 ▲51.8% $15.20M −$12.61M '23 Q3 23-11-01 ▲33.2% $14.03M −$14.10M '23 Q4 24-01-10 ▲52.1% $11.68M −$29.28M '24 Q1 24-06-26 ▼17.4% $11.59M −$41.40M '24 Q4 25-03-05 ▲109.3% $24.45M −$45.20M '25 Q1 25-05-07 ▼43.7% $5.33M −$59.43M '25 Q2 25-08-06 ▼90.8% $966,000 −$59.73M '25 Q3 25-11-05 ▼94.7% $619,000 −$67.61M '25 Q4 26-03-04 ▼97.2% $696,000 −$84.83M '26 Q1 26-05-06 LATEST ▼90.5% $507,000 −$94.47M '26 Q2 26-08-17
Conference
Investor event
2026-09-15
EyePoint, Inc. (EYPT) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-17
EyePoint, Inc. (EYPT) Q2 2026 Earnings Call
Revenue
$507,000
▼ 90.5% YoY
Diluted EPS
$-1.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
EyePoint, Inc. (EYPT) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
EyePoint, Inc. (EYPT) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
Confident tone DuraVue Phase 3 wet AMD readouts (Lugano and Lucia) DME Phase 3 program (COMO and CAPRI) enrollment Multi-mechanism of action (VEGF, PDGF, IL-6/JAK1)
Revenue
$696,000
▼ 97.2% YoY
Diluted EPS
$-0.99
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
Confident tone DuraVu wet AMD Phase 3 (Lugano/LUCIA) DuraVu DME Phase 3 (COMO/CAPRI) Differentiated mechanism of action
Revenue
$619,000*
▼ 94.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
EyePoint, Inc. (EYPT) Q3 2025 Earnings Call Transcript
Confident tone DURAVYU in wet AMD Phase III (LUGANO/LUCIA) DURAVYU in DME Phase III (COMO/CAPRI) Vorolanib multi-mechanism (VEGF, PDGF, IL-6)
Revenue
$966,000
▼ 90.8% YoY
Diluted EPS
$-0.85
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
EyePoint, Inc. (EYPT) Q2 2025 Earnings Call Transcript
Confident tone DURAVYU Phase III trials in wet-AMD (LUGANO and LUCIA) DME (VERONA trial) pipeline expansion Competitive landscape and first-mover advantage
Revenue
$5.33M
▼ 43.7% YoY
Diluted EPS
$-0.85
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
EyePoint, Inc. (EYPT) Q1 2025 Earnings Call Transcript
Confident tone DURAVYU Phase 3 Wet AMD Trials (LUGANO/LUCIA) Diabetic Macular Edema (DME) Program Regulatory and Trial Design
Revenue
$24.45M
▲ 109.3% YoY
Diluted EPS
$-0.65
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-05
EyePoint, Inc. (EYPT) Q4 2024 Earnings Call Transcript
Confident tone DURAVYU Phase 3 wet AMD trials (LUGANO and LUCIA) DURAVYU Phase 2 VERONA trial in DME De-prioritized razuprotafib program
Revenue
$11.59M*
▼ 17.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q1
2024-06-26
EyePoint, Inc. (EYPT) Q1 2024 Earnings Call
Revenue
$11.68M
▲ 52.1% YoY
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-10
EyePoint, Inc. (EYPT) Q4 2023 Earnings Call Transcript
Confident tone EYP-1901 pipeline progress NPDR / DME indications DAVIO 2 Phase 2 results
Revenue
$14.03M*
▲ 33.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-01
EyePoint, Inc. (EYPT) Q3 2023 Earnings Call Transcript
Revenue
$15.20M
▲ 51.8% YoY
Diluted EPS
$-0.33
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
EyePoint, Inc. (EYPT) Q2 2023 Earnings Call Transcript
Revenue
$9.11M
▼ 21.3% YoY
Diluted EPS
$-0.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
EyePoint, Inc. (EYPT) Q1 2023 Earnings Call Transcript
Revenue
$7.68M
▼ 17.3% YoY
Diluted EPS
$-0.56
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-06
EyePoint, Inc. (EYPT) Q4 2022 Earnings Call Transcript
Revenue
$10.53M*
▼ 8.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
EyePoint, Inc. (EYPT) Q3 2022 Earnings Call Transcript
Revenue
$10.01M
▲ 10.5% YoY
Diluted EPS
$-0.49
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-07-18
EyePoint, Inc. (EYPT) Q2 2022 Earnings Call Transcript
Revenue
$11.56M
▲ 28.3% YoY
Diluted EPS
$-0.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
EyePoint, Inc. (EYPT) Q1 2022 Earnings Call Transcript
Revenue
$9.29M
▲ 26.9% YoY
Diluted EPS
$-0.56
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-03
EyePoint, Inc. (EYPT) Q4 2021 Earnings Call Transcript
Revenue
$11.54M*
▲ 61.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-03
EyePoint, Inc. (EYPT) Q3 2021 Earnings Call Transcript
Revenue
$9.06M
▼ 42.3% YoY
Diluted EPS
$-0.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
EyePoint, Inc. (EYPT) Q2 2021 Earnings Call Transcript
Revenue
$9.01M
▲ 118.7% YoY
Diluted EPS
$-0.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
EyePoint, Inc. (EYPT) Q1 2021 Earnings Call Transcript
Revenue
$7.32M
▼ 2.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-04
EyePoint, Inc. (EYPT) Q4 2020 Earnings Call Transcript
Revenue
$7.13M*
▼ 17.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-07
EyePoint, Inc. (EYPT) Q3 2020 Earnings Call Transcript
Revenue
$15.70M
▲ 525.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
EyePoint, Inc. (EYPT) Q2 2020 Earnings Call Transcript
Revenue
$4.12M
▼ 42.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
EyePoint, Inc. (EYPT) Q1 2020 Earnings Call Transcript
Revenue
$7.49M
▲ 272.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
EyePoint, Inc. (EYPT) Q4 2019 Earnings Call
Revenue
$8.63M
▲ 253.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 webcasts
Key facts CIK 1314102 CUSIP 30233G209 13F (30d) 4 filings 4 filers Visit website Investor relations